Form 4: BioVie Inc. CEO Acquires Stock Options

BioVie Inc.'s CEO, Cuong V Do, acquired 104,502 stock options on December 20, 2024, which vest over three years.

Summary

• Cuong V Do, the President and CEO of BioVie Inc., has acquired 104,502 stock options.
• The transaction occurred on December 20, 2024.
• The options have an exercise price of $1.90.
• The options vest in three equal installments on December 20, 2024, December 20, 2025, and December 20, 2026.
• The options expire on December 20, 2034.
• The options are indirectly held through Do & Rickles Investments LLC.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants to the CEO, which is neither particularly positive nor negative. It is a standard practice in executive compensation.

Positives

• The acquisition of stock options by the CEO could indicate confidence in the company's future performance.
• The vesting schedule of the options may incentivize the CEO to focus on long-term value creation.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives acquire or dispose of company securities. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, similar to companies like Amgen, Gilead, and Regeneron.
• The vesting schedule of three years is also typical for such grants, aligning with industry practices.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it aligns the CEO's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, executive compensation, BioVie Inc., BIVI, Cuong V Do